Status:
ACTIVE_NOT_RECRUITING
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Geographic Atrophy (GA)
Lead Sponsor:
Annexon, Inc.
Conditions:
Geographic Atrophy
Eligibility:
All Genders
50+ years
Phase:
PHASE3
Brief Summary
The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with GA secondary to age-related macular degeneration (AMD).
Eligibility Criteria
Inclusion
- Diagnosis of GA of the macula secondary to AMD as determined by the Investigator and confirmed by the independent Central Reading Center.
Exclusion
- Geographic atrophy due to other causes than AMD such as Stargardt disease, cone-rod dystrophy, pathologic myopia, or toxic maculopathies (for example, plaquenil maculopathy) in either eye.
- NOTE: Other protocol-defined inclusion and exclusion criteria may apply.
Key Trial Info
Start Date :
July 30 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 31 2027
Estimated Enrollment :
659 Patients enrolled
Trial Details
Trial ID
NCT06510816
Start Date
July 30 2024
End Date
October 31 2027
Last Update
November 6 2025
Active Locations (130)
Enter a location and click search to find clinical trials sorted by distance.
1
Retina Macula Institute of Arizona
Scottsdale, Arizona, United States, 85255
2
Retina-Vitreous Associates Medical Group
Beverly Hills, California, United States, 90211
3
RCOC Clinical Research Institute Inc
Fullerton, California, United States, 92835
4
Global Research Management
Glendale, California, United States, 91204